Figure 4. Effects of empagliflozin versus placebo on the primary outcome and kidney disease progression by serum uric acid concentration at randomisation.

*To convert uric acid to mg/dL, divide by 59.48 (380 μmol/L ≈ 6.4 mg/dL; 470 μmol/L ≈ 7.9 mg/dL). Progression of kidney disease is defined as end-stage kidney disease (initiation of maintenance dialysis or kidney transplant), a sustained decrease in eGFR to <10 mL/min/1.73m², a sustained decrease in eGFR of at least 40% from baseline, or death from renal causes. Reasons for missing uric acid: analyses were not conducted in participants from China (n=986) or participants who did not provide additional optional consent for long-term sample storage for biochemical analysis. P_trend tests for trend across the 3 non-missing categories.